Recently, we conducted two pivotal clinical trials assessing the efficacy of programmed cell death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors in combination with chemotherapy for ES‐SCLC in the first‐line setting. This evidence concerns the gene CD274 and small cell lung carcinoma.